Risk of Intrahepatic and Extrahepatic Cancers in Hepatitis C Virus Infection: A Nationwide Cohort Study in Korea, 2005–2023
Liver International · 2026-06 · 46 (6)
DOI: 10.1111/liv.70664 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Liver International, online erschienen am 05.05.2026. Verfasst von Yoon Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health & AI, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea. Hauptthemen laut MEDLINE: Hepacivirus, Hepatitis C, Liver Neoplasms, Antiviral Agents. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Cancer Center.
Abstract (Originalsprache)
Background & Aims We evaluated the association between hepatitis C virus (HCV) infection and the risk of intrahepatic and extrahepatic cancers. Specifically, we compared “1st” versus “1st or 2nd” primary cancers to capture the true disease burden, which is often underestimated in conventional analyses. Additionally, we evaluated the chemopreventive effect of direct‐acting antiviral (DAA) therapy on these risks.
Methods
Using the Korean National Health Insurance database (2005–2023), we compared 119 565 HCV‐infected individuals with 2 267 700 controls. Adjusted subdistribution hazard ratios (aHRs) were calculated using competing risk models. Direct‐acting antivirals (DAA) effectiveness was evaluated in a sub‐cohort of 23 147 patients (2016–2020) using time‐dependent Cox models to account for immortal time bias.
Results
In the analysis of 1st or 2nd cancers, HCV infection significantly increased the risk of intrahepatic (aHR 16.35; 95% CI, 15.81–16.90) and extrahepatic cancers (aHR 1.14; 95% CI, 1.12–1.16). Notably, expanding the endpoint to include 2nd cancers increased the aHR for extrahepatic cancer from 1.09 to 1.14, indicating that traditional analyses underestimate the true burden. Significant risk elevations were observed for haematological, biliary, pancreatic, and renal cancers. In the DAA sub‐cohort analysis using the time‐dependent model, DAA treatment significantly reduced the risk of intrahepatic cancer (aHR 0.54–0.61) and extrahepatic cancers (aHR 0.77) after adjusting for competing risks.
Conclusions
HCV infection significantly increases both intrahepatic and extrahepatic cancer risks. Excluding 2nd cancer underestimates this burden. Given that DAA therapy significantly reduces the risk of both intrahepatic and extrahepatic cancers, accelerating HCV elimination policies is imperative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health & AI, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
- Center for Liver and Pancreatobiliary Cancer, Department of Internal Medicine, National Cancer Center, Goyang, Korea.
- Center for Liver and Pancreatobiliary Cancer, Department of Surgery, National Cancer Center, Goyang, Korea.
- Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.
Förderung
- National Cancer Center
Zitieren
APA
Park, Y., Kim, B. W., Oh, J. K., Kim, B. H., Park, S. J., Kim, K. A., & Ki, M. (2026). Risk of Intrahepatic and Extrahepatic Cancers in Hepatitis C Virus Infection: A Nationwide Cohort Study in Korea, 2005–2023. Liver International, 46(6). https://doi.org/10.1111/liv.70664
Vancouver
Park Y, Kim BW, Oh JK, Kim BH, Park SJ, Kim KA, et al. Risk of Intrahepatic and Extrahepatic Cancers in Hepatitis C Virus Infection: A Nationwide Cohort Study in Korea, 2005–2023. Liver International. 2026;46(6). doi:10.1111/liv.70664
BibTeX
@article{Park2026,
author = {Park, Yoon and Kim, Byung-Woo and Oh, Jin-Kyoung and Kim, Bo Hyun and Park, Sang-Jae and Kim, Kyung-Ah and Ki, Moran},
title = {Risk of Intrahepatic and Extrahepatic Cancers in Hepatitis C Virus Infection: A Nationwide Cohort Study in Korea, 2005–2023},
journal = {Liver International},
year = {2026},
volume = {46},
number = {6},
doi = {10.1111/liv.70664}
}
EUVIMED